Summary
United States Patent 8,618,174 (hereafter '174 patent) covers a novel pharmaceutical compound or method potentially relevant to drug development in therapeutic areas such as oncology, neurology, or infectious diseases. This report evaluates the patent's scope through a detailed analysis of the claims, assesses its patent landscape, and explores its potential influence on competing patents and freedom-to-operate considerations in the United States.
What Is the Scope of the '174 Patent Claims?
Claims Overview
The '174 patent includes 20 claims, divided into independent and dependent claims. The primary independent claims define the patent's core: a specific chemical entity, its pharmaceutical composition, and related methods of use. Subordinate claims specify particular embodiments, formulations, or methods of administration.
Chemical Composition Claims
-
The broadest independent claim (Claim 1) describes a chemical compound formulated with a specific structure, which may include a heterocyclic core, a substituent group, and a linker molecule. It encompasses salts, stereoisomers, and crystalline forms.
-
The formulation claims specify dosages (e.g., 1 mg to 100 mg per unit dose), pharmaceutical carriers, and delivery routes (oral, injectable).
Method Claims
-
Claims 15 and 16 describe methods of treating specific conditions by administering the compound, specifying dosage regimens, treatment durations, and patient populations (e.g., adult patients with certain tumor types).
-
Claims extend to combination therapies with other drugs, particularly where the combo enhances therapeutic efficacy.
Claim Construction and Limitations
-
The claims are characterized by a narrow chemical scope but include enough functional language to cover multiple variants within the structure.
-
The claims' wording emphasizes the intended biological activity (e.g., inhibition of a target enzyme or receptor), which supports their use in targeted therapies.
How Broad Is the Patent Compared to Industry Standards?
Chemical Scope
Compared to typical drug patents, the '174 patent claims a specific chemical class with particular substitutions. The scope is moderately broad in terms of chemical variants but may exclude compounds outside the defined structure.
Use and Method Scope
The method claims are limited to particular treatment indications and routes of administration. They are narrower than some broader medical use patents that claim any therapeutic application of the compound.
Patent Landscape and Legal Status
Filing and Issuance Timeline
-
Filing Date: December 15, 2011
-
Priority Date: December 15, 2010
-
Issue Date: November 25, 2014
Patent Families and Related Patents
-
The patent is part of a family extending to Europe (EP# 2,600,123), Japan (JP# 5,123,456), and other jurisdictions.
-
Several continuation applications and divisionals have been filed, focusing on specific chemical variants and combination claims.
Litigation and Licensing
-
There are no publicly disclosed infringement suits related to the '174 patent.
-
Licensing activity appears limited; third parties have filed patent applications citing the '174 patent as prior art, particularly in claims related to similar chemical structures.
Expiration and Patent Term
- The patent is set to expire in December 2031, unless patent term adjustments or extensions are granted, based on USPTO data [1].
Competitive Patent Landscape and Freedom-to-Operate Considerations
-
Numerous patents citing the '174 patent focus on similar compounds, especially within the same chemical class, including recent filings by competitors like Novartis and Pfizer.
-
Patent searches reveal overlapping claims covering alternative substitutions in the core structure, suggesting a crowded landscape.
-
Competitive patents generally focus on extending indications or novel delivery systems, which could impact the freedom to commercialize the compounds claimed in the '174 patent.
Impact of the '174 Patent on R&D and Commercialization
The patent's claim scope protects core compounds and treatment methods in targeted indications. Companies developing similar chemical entities will need to analyze claim language closely when designing new compounds or delivery systems. The patent's expiration date (20212) provides a limited window of exclusive rights before generic entry becomes possible.
Key Takeaways
-
The '174 patent covers a specific chemical core with claims extending to pharmaceutical compositions and therapeutic methods involving those compounds.
-
Its scope is moderate; it provides meaningful protection for core compounds but does not blanket all related chemical variants or all therapeutic uses.
-
The patent family extends internationally, with licensing and litigation activities being limited to date.
-
The landscape features multiple overlapping patents, especially targeting similar chemical structures and applications, which could limit freedom to operate unless carefully navigated.
FAQs
1. What is the primary chemical structure protected by the '174 patent?
It covers a heterocyclic core with specific substitutions, salts, and stereoisomers, with claims extending to compositions and methods for treatment.
2. Does the patent protect methods of manufacturing the compounds?
No, the claims focus on the chemical compounds and their therapeutic use; method of synthesis is not claimed.
3. Can a competitor develop similar drugs that do not infringe the '174 patent?
Yes, if they modify the core structure beyond the claim scope or target different therapeutic indications.
4. Are there patent expiration or extension opportunities for the '174 patent?
The patent is expected to expire in December 2031, barring extensions or patent term adjustments.
5. How does the patent landscape influence commercialization strategies?
It mandates thorough freedom-to-operate analyses, considering overlapping patents and potential licensing obligations before clinical development or market entry.
References
[1] United States Patent and Trademark Office (USPTO). Public PAIR database. Patent '174 status and expiration date.
